Add BrightSurf on Google Email

Disproportionately more opioids prescribed in poorer areas

A recent study found that people in poorer areas receive three times the prescriptions for opioids than those in wealthier areas, despite a decline in overall opioid use in Canada. The research highlights the persistence of inequalities in healthcare and the need for targeted interventions to mitigate the risks of opioid misuse.

SourceUniversity of Waterloo·JournalDrugs - Real World Outcomes·TypeData/statistical analysis·DateJul 17, 2025

Be Well Texas at UT Health San Antonio to lead major statewide expansion of opioid use disorder and recovery services

The Be Well Texas initiative, led by the University of Texas Health Science Center at San Antonio, will expand access to opioid use disorder treatment services and recovery support across rural and urban communities. This major statewide expansion aims to reduce overdose deaths and build a lasting recovery infrastructure.

Improved prognosis for chronic thromboembolic pulmonary hypertension over recent decades

Recent studies have revealed significant improvements in patient prognosis for chronic thromboembolic pulmonary hypertension (CTEPH) over the past few decades. Advances in surgical techniques, drug development, and multimodal therapies have led to increased treatment rates and improved survival rates among patients.

SourceNational Cerebral and Cardiovascular Center·JournalEuropean Respiratory Journal·DateJul 14, 2025

Weekly injection could be life changing for Parkinson’s patients

Scientists at University of South Australia developed a long-acting injectable formulation that delivers levodopa and carbidopa over a week, reducing the need for multiple daily tablets. The biodegradable formulation improves treatment outcomes and patient compliance, offering a potential game-changer for Parkinson's care.

SourceUniversity of South Australia·JournalDrug Delivery and Translational Research·TypeExperimental study·DateJul 13, 2025

New gene therapy delivery device could let hospitals create personalized nanomedicines on-demand

A new gene therapy delivery device called NANOSPRESSO could revolutionize how hospitals treat rare diseases by allowing them to create personalized nanomedicines in-house. This democratized approach to precision medicine could boost access to low-cost bespoke gene and RNA therapies, especially in low-resource settings.

SourceFrontiers·JournalFrontiers in Science·TypeSystematic review·DateJun 26, 2025

Novel study uncovers the critical role of ADAM10 protein in the development of retinal disorders

A recent study published in The American Journal of Pathology has discovered that ADAM10 regulates abnormal blood vessel growth in the retina, which can cause vision loss or impairment. The findings suggest that targeting ADAM10 or its downstream effectors, such as Ephrin B2, may offer novel strategies for managing or preventing retina...

SourceElsevier·JournalAmerican Journal Of Pathology·TypeExperimental study·DateJun 24, 2025

Major discovery by UT Health San Antonio scientists sheds light on cancer drug resistance

Researchers at UT Health San Antonio have made a major discovery in understanding cancer drug resistance, specifically in BRCA1-deficient cancers treated with PARP inhibitors. The study reveals that problems in the CST complex can cause resistance to these drugs, opening doors to new therapies and personalized treatments.

New hope for patients with Werner syndrome

Researchers have discovered that nicotinamide riboside supplementation significantly improves NAD+ levels, reducing arterial stiffness, skin ulcer area, and kidney dysfunction. This breakthrough offers new hope for patients with Werner syndrome who lack effective treatment options.

SourceChiba University·JournalAging Cell·TypeExperimental study·DateJun 5, 2025

International study: Asthma drug could help to treat a rare neurological disorder

A new study published by Martin-Luther-Universität Halle-Wittenberg found that theophylline significantly improved symptoms and quality of life for patients with ADCY5-related dyskinesia. The treatment yielded impressive results, including reduced muscle twitches, improved gait, and better psychosocial well-being.

SourceMartin-Luther-Universität Halle-Wittenberg·JournalMovement Disorders·TypeExperimental study·DateJun 3, 2025

How PM2.5 wrecks your airways and how the damage might be reversed

Exposure to PM2.5 air pollutants impairs mucociliary clearance, a key protective mechanism in the respiratory tract, leading to severe airway damage and respiratory diseases. Researchers have identified the enzyme ALDH1A1 as a potential therapeutic target to reverse this damage and strengthen our respiratory defenses.

SourceImmunology Frontier Research Center (IFReC) - Osaka University·JournalJournal of Clinical Investigation·TypeExperimental study·DateJun 2, 2025

Experimental Drug Development Centre granted US FDA fast track designation for antibody-drug conjugate EBC-129 to treat pancreatic ductal adenocarcinoma

The Experimental Drug Development Centre's EBC-129, an antibody-drug conjugate targeting pancreatic cancer, has received FDA fast track designation. The treatment is undergoing Phase 1 clinical trials and aims to provide new treatment options for patients with solid tumours.

Never too old: medication improves survival rates after a first heart attack even in patients over 90 years old

A study found that prescribing guideline-directed medical treatment to patients 90 years and older following their first heart attack can improve survival rates. The greatest benefit was observed in those who received all four recommended therapies, including beta-blockers and renin-angiotensin-aldosterone system inhibitors.

SourceElsevier·JournalCanadian Journal of Cardiology·TypeData/statistical analysis·DateMay 22, 2025

Cannabis use disorder is increasing rapidly, especially among older adults and people living with HIV

A new study finds that cannabis use disorder diagnoses rose substantially across all age groups, race/ethnicity, and comorbidity subgroups nationwide from 2000 to 2022. People living with HIV experienced the greatest relative increase in CUD diagnoses, particularly among older adults.

SourceBoston University School of Public Health·JournalJournal of Addiction Medicine·TypeObservational study·DateMay 21, 2025

Oxygen deprivation promotes colon cancer growth

Researchers at The University of Osaka found that localized oxygen deficiency in colon tumors can promote tumor growth by transforming normal fibroblasts into inflammatory fibroblasts. These altered cells release factors that help tumors grow, offering a potential new target for cancer therapy.

SourceThe University of Osaka·JournalNature Communications·TypeExperimental study·DateMay 20, 2025

First all-oral treatment for a rare but deadly strain of sleeping sickness now available and being used to treat patients in endemic countries in Africa

A breakthrough all-oral treatment for a rare but deadly strain of sleeping sickness is now available, revolutionizing care for patients in endemic countries. Fexinidazole Winthrop has been approved for use in several African countries and is being distributed by WHO, offering a safer alternative to existing treatments.

GLP-1 drugs are helpful for children who are living with severe obesity, data from Swedish clinic indicates

A new study published at the European Congress on Obesity suggests that GLP-1 agonist drugs can lead to a clinically relevant change in BMI for children with severe obesity. In this study, 30% of children who received GLP-1 drugs experienced a significant reduction in BMI, compared to around 27% of those who did not receive them.

Race and ethnicity often not reported in trials of medications for mental health conditions

A new study found that only 39% of clinical trials report the race or ethnicity of participants involved. The research highlights the need for more comprehensive reporting and recruitment practices to ensure studies better reflect diverse populations globally. This is crucial for developing inclusive, effective, and equitable treatments.

SourceUniversity of Southampton·JournalJAMA Psychiatry·TypeSystematic review·DateMay 7, 2025

Adding perioperative pembrolizumab to standard of care improves outcomes in patients with newly diagnosed head and neck cancer

A phase III clinical trial found that adding pembrolizumab before and after surgery improved responses and survival in patients with previously untreated, locally advanced head and neck squamous cell carcinoma. Patients treated with pembrolizumab were at least 27% less likely to have experienced recurrence.

This injected protein-like polymer helps tissues heal after a heart attack

Researchers developed a new therapy that can be injected intravenously right after a heart attack to promote healing and prevent heart failure. The therapy both prompts the immune system to encourage tissue repair and promotes survival of heart muscle cells after a heart attack, showing effectiveness up to five weeks after injection.

SourceUniversity of California - San Diego·JournalAdvanced Materials·TypeExperimental study·DateApr 25, 2025

Radioiodine therapy improves relative survival rates of differentiated thyroid cancer patients

A new study finds that radioiodine therapy significantly increases relative survival rates in differentiated thyroid cancer patients, with benefits observed across low-, intermediate-, and high-risk subgroups. The treatment reduces recurrence rates and improves long-term survival in high-risk groups, while also showing promise for low-...

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateApr 25, 2025

For colon cancer that no longer responds to treatment, a new drug combination offers hope

A Phase 3 clinical trial has shown that a combination of sotorasib and panitumumab significantly improves progression-free survival in patients with KRAS G12C metastatic colorectal cancer. The study found improved overall survival rates, with the high-dose sotorasib group experiencing a 30% prolongation compared to standard care.

SourceCity of Hope·JournalJournal of Clinical Oncology·TypeRandomized controlled/clinical trial·DateApr 24, 2025

Comparative analysis of bioactive ingredients and medicinal functions of natural and cultivated Ophiocordyceps sinensis (berk.)

This review compares the bioactive components and medicinal properties of natural and cultivated O. sinensis, highlighting differences in composition and effectiveness for specific therapeutic uses. Polysaccharides, nucleosides, sterols, and amino acids contribute to their health benefits, with natural specimens often exhibiting higher...

SourceXia & He Publishing Inc.·JournalFuture Integrative Medicine·DateApr 23, 2025

Hospitalized patients who receive alcohol use disorder treatment can substantially reduce heavy drinking

A new study found that both oral and injectable forms of naltrexone are effective in reducing heavy drinking among hospitalized patients. The medication was administered before discharge, resulting in a significant decrease in heavy drinking within the last 30 days of the three-month follow-up period.

SourceBoston University School of Public Health·JournalJAMA Internal Medicine·TypeRandomized controlled/clinical trial·DateApr 21, 2025

UT Health San Antonio-led discovery means IV medication could be taken orally for range of cancer, Alzheimer’s treatments

A UT Health San Antonio-led discovery could redefine drug discovery by turning IV medications into orally administered treatments for brain cancer, Alzheimer’s disease, and other complex conditions. The new strategy uses a protein receptor called CD36 to efficiently deliver large molecules into cells.

SourceUniversity of Texas Health Science Center at San Antonio·JournalCell·TypeExperimental study·DateApr 21, 2025

Scientists hack cell entry to supercharge cancer drugs

Researchers at Duke University and colleagues discover a way to improve the uptake of cancer-fighting drugs called PROTACs by leveraging the CD36 protein. This approach delivered up to 23 times more potent treatment without compromising stability or solubility, paving the way for effective medications.

SourceDuke University·JournalCell·TypeExperimental study·DateApr 17, 2025